TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions
Nitin H Shirole,
Debjani Pal,
Edward R Kastenhuber,
Serif Senturk,
Joseph Boroda,
Paola Pisterzi,
Madison Miller,
Gustavo Munoz,
Marko Anderluh,
Marc Ladanyi,
Scott W Lowe,
Raffaella Sordella
Affiliations
Nitin H Shirole
Cold Spring Harbor Laboratory, Cold Spring Harbor, United States; Graduate Program in Genetics, Stony Brook University, Stony Brook, United States
Debjani Pal
Cold Spring Harbor Laboratory, Cold Spring Harbor, United States; Graduate Program in Molecular and Cellular Biology, Stony Brook University, Stony Brook, United States
Edward R Kastenhuber
Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States
Serif Senturk
Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
Joseph Boroda
Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
Paola Pisterzi
Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
Madison Miller
Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
Gustavo Munoz
Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
Marko Anderluh
Department of Medicinal Chemistry, University of Ljubljana, Ljubljana, Slovenia
Marc Ladanyi
Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States
Scott W Lowe
Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, United States
Cold Spring Harbor Laboratory, Cold Spring Harbor, United States; Graduate Program in Genetics, Stony Brook University, Stony Brook, United States; Graduate Program in Molecular and Cellular Biology, Stony Brook University, Stony Brook, United States
TP53 truncating mutations are common in human tumors and are thought to give rise to p53-null alleles. Here, we show that TP53 exon-6 truncating mutations occur at higher than expected frequencies and produce proteins that lack canonical p53 tumor suppressor activities but promote cancer cell proliferation, survival, and metastasis. Functionally and molecularly, these p53 mutants resemble the naturally occurring alternative p53 splice variant, p53-psi. Accordingly, these mutants can localize to the mitochondria where they promote tumor phenotypes by binding and activating the mitochondria inner pore permeability regulator, Cyclophilin D (CypD). Together, our studies reveal that TP53 exon-6 truncating mutations, contrary to current beliefs, act beyond p53 loss to promote tumorigenesis, and could inform the development of strategies to target cancers driven by these prevalent mutations.